A team of medical device developers, neuroscientists, surgeons and engineers from the University of California San Diego is working on developing better customized maps that will be useful to physicians during brain tumor removal surgery.

Maps do already exist that physicians can reference. However, one individual’s brain isn’t the same as another’s, which is why customized maps are needed. Additionally, an individual’s brain may sometimes reorganize itself as a response to damage caused by things such as growing tumors, which can make it even harder to remove the tumor.

This is where sensors enter the picture. Surgical teams can utilize these sensors in determining the parts of the brain that are activated when actions such as moving or speaking are carried out, which can then be used by the team to come up with a map of the parts to avoid when performing the surgery. This will also help minimize possible damage caused by removing the tumor.

More specifically, the researchers are centered on enhancing the performance of the sensor mats, which are placed right on the surface of the brain. These enhanced sensor grids are also being utilized in the enhancement of epilepsy treatments. They enable surgeons to record brain signals when electrical stimulation is applied. Researchers are hopeful that further work in the area may aid in the development of better treatments of epilepsy and maybe even find the root cause of the disease.

The partnership between physicians and engineers was started when Eric Halgreen, a professor of radiology and neurosciences from UC San Diego Health, met. Shadi Dayeh, an electrical engineering professor from the institution’s Jacobs School of Engineering. The team has developed enhanced versions of sensor mats that can directly read signals from the surface of an individual’s brain during surgery.

Dayeh and the group of researchers have enhanced these systems in various ways, including increasing the density of single sensors in the grids as well as increasing the size of the sensor grids. In addition, they have developed sensors with grids that are packed more tightly, which enables surgeons to come up with higher resolution custom maps of an individual’s brain. The grids are also supple, which enables the surgeons to carefully follow the fluctuations of the brain’s surface, which in turn boosts signal reading.

Dayeh and his team recently established a startup with the objective to allow more clinicians to access the sensor grids they are creating.

The field of neurology diagnostics is evolving rapidly with established firms such as Brain Scientific Inc. (OTCQB: BRSF) unveiling technologies that could potentially disrupt how the medical community has been diagnosing neurological issues in patients.

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

New research conducted by researchers from the University of California-Santa Cruz has found that an individual dose of tabernanthalog (“TBG”) can repair neural circuits in the brain that are damaged by stress, enhance neuronal connection regrowth and remedy behavioral deficits such as cognitive inflexibility and anxiety that are caused by stress.

TBG is a new compound that has a structure similar to ibogaine, a psychedelic drug.  Prior studies have found that while ibogaine has the potential to treat addiction, it is also a powerful hallucinogen and can cause severe heart arrhythmias.

However, unlike ibogaine, TBG lacks hallucinogenic and toxic effects. Researchers have found that it can reverse the effects of stress, as observed in rodent models. The study was reported in “Molecular Psychiatry” last month.

Prof. Yi Zuo, who was the corresponding author of the study, explained that researchers were surprised to find that a low dose of this treatment had such a remarkable effect in a day. Zuo, who focuses on developmental, cell and molecular biology at the institution, noted that she had found it hard to believe even after she’d seen the preliminary data.

The compound was developed at the university in the laboratory of David Olson, who is a co-author of the study.

Zuo’s laboratory had collaborated with Olson on the preliminary studies of the compound, which were published last year in the “Nature” journal. This new study centered on the harmful effects of stress, which entailed rodent models being subjected to unpredictable mild stressors over a few days.

Stress is known to cause decreased flexibility in decision-making, deficiencies in sensory processing and increased anxiety on the behavioral level. Additionally, stress adjusts the neuronal circuitry and damages the connections between neurons in the brain, which brings about an imbalance between inhibition and excitation.

Zuo explained that during the study, researchers found that TBG undid of the effects of stress; Zuo noted that the team’s research offered important insights into the mechanisms underlying the healing effects of psychedelic analogs on mental conditions. She added that it would also be beneficial to future researchers who would like to better understand their circuit and cellular mechanisms.

Preliminary studies of TBG also discovered that it decreased addictive behaviors and had antidepressant effects in mice. However, the compound is yet to be tested on people. Researchers note though that unlike ibogaine, TBG doesn’t bring about the head-twitch behavior caused by hallucinogens and is also not toxic, as observed in animal tests.

Psychedelics are indeed promising to avail solutions to many of the mental and behavioral challenges societies face. With the work being done by entities such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), chances are high that approved psychedelic-based formulations may soon be available.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Last month, a bill that would make certain that CBD products derived from hemp fell under the domain of the FDA in the same way as other legalized products added to beverages, foods and dietary supplements, was introduced in the Senate. The legislation, dubbed the Hemp Access and Consumer Safety Act, was tabled by Oregon senators Ron Wyden and Jeff Merkley and Kentucky Sen. Rand Paul.

Wyden stated that CBD products were legally being produced and used across the country. However, because the U.S. Food and Drug Administration hadn’t updated its regulations, producers and consumers remained in a gray zone. Wyden added that it had been more than two years since he’d collaborated with his colleagues to call for Congress to legalize products obtained from hemp as well as hemp itself. He noted that the time had come for the federal regulator to update its regulations, for the good of farmers and consumers in America.

Earlier in 2018, the U.S. Congress approved the Agriculture Improvement Act, which removed industrial hemp from the first Schedule of the CSA, where it had been classified. This led to the legalization of the sale and production of hemp derivatives and industrial hemp, including cannabidiol (“CBD”). Despite this move, the FDA still outlaws any new beverage, food or dietary ingredient from being traded across state borders if it had ever been approved or studied as a drug, which is the case for CBD.

Epidiolex is the only drug approved by the FDA for treating seizures linked to Lenox-Gastaut syndrome, which had CBD in a highly purified form. While the FDA possesses the mandate to exempt any substance from prohibition, it has claimed that it has a limited grasp of CBD’s safety profile, as well as other compounds derived from cannabis. Thus far, the only move made by the agency with respect to CBD is conveying warming letters to firms that make therapeutic claims about the substance.

The sponsors of this hemp access legislation are hopeful that another bill of Congress may pave a path for the legal use of CBD in beverages, supplements and food. Paul notes that this latest bill will direct the agency to regulate all hemp products adequately, which provides relief to merchants, processors and farmers. On the other hand, Merkley asserts that the bill will allow for the issuance of clear guidelines for CBD products obtained from hemp.

The sponsors add that the legislation will also place emphasis on consumer safety as it will require manufacturers to adhere to the existing federal laws for products that contain CBD.

Once this legislation is enacted, players in the CBD space such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) will have more clear regulations to guide them, and the sector could thrive as a result.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Researchers from the Rogel Cancer Center at the University of Michigan have sequenced the RNA of single cells in cancerous and benign kidney tumors. Using that information, they have  determined cells from which various subtypes originate and how the tumor micro-environment affects the development of cancer and an individual’s response to treatment.

The researchers’ discoveries were reported in “Proceedings of the National Academy of Sciences” journal and will be useful in helping better understand what impacts renal cell carcinoma and in assisting oncologists in choosing the best treatment for each patient.

This, in turn, will be beneficial to patients, given that kidney cancers behave differently and respond differently to treatments such as immunotherapy, which results in different outcomes for each patient.

Director of the Michigan Center for Translational Pathology Arul Chinnaiyan, who was also the author of the study, explained that the RNA sequencing of individual cells was important as it enabled the researchers to observe gene expression patterns in every cell, which led them to the discovery of the mechanisms at play in the tumor micro-environment. This can forecast overall survival. Chinnaiyan is also a Michigan Medicine S.P. Hicks Professor of Pathology.

For their research, the researchers collected kidney samples from patients who had undergone partial nephrectomies at the University of Michigan Health System. The tumor specimens that were used for the study were stained and air dried using the Quickdiff process before individual-cell dissociation. After this, all tumor and benign specimens were evaluated with H&E-stained sections (hematoxylin and eosin) by pathologists. The researchers also acquired medullary and separate cortical specimens. They utilized freshly collected tumor and benign kidney samples for individual-cell isolation, with the remaining tissues being used in bulk tissue DNA/RNA isolation.

During their study, the scientists generated gene expression atlases of both renal cell carcinoma and normal kidney cell samples. They then forecasted the putative cell of origin for more than 10 subtypes of renal cell cancer.

The researchers then conducted an analysis showing interactions and pathways in the tumor micro-environment that forecasted if the tumor would respond to immunotherapy. This information could help researchers develop biomarkers to help guide the treatment of kidney cancer.

Chinnaiyan noted that understanding the type of cell where a cancer arises would enable researchers to develop more specific treatments for that type of cancer while also allowing them to better understand a patient’s response to treatments.

The research was approved by the Institutional Review Board at the University of Michigan, with all patients involved in the study providing informed consent.

Such scientific investigations build onto the work of personalizing cancer care as championed by companies such as Predictive Oncology (NASDAQ: POAI) as a way of improving the treatment outcome for each patient.

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Electric vehicles (“EVs”) are poised to replace internal combustion engine (“ICE”) vehicles over the next couple of decades, but a slew of issues stand in the way of mass EV adoption. The United States is working towards achieving net-zero emissions by 2050, and electric vehicles will play a major role in reducing the country’s reliance on fossil fuels and cutting emissions. However, America’s EV charging infrastructure is not developed enough to support an influx of electric vehicles on the roads.

Not only does America have a woefully insufficient public charging network, but most chargers are slow, meaning drivers have to spend hours at the chargers to get their vehicles fully charged. If you’re planning a road trip or just traveling long distance, you will have to carefully plan your route to make sure you don’t run out of juice without a charging station in sight. And even if you do find a station, the plugs may not be compatible with your vehicle because some companies, including Tesla, have built networks that are only accessible by their vehicles.

Consequently, a YouGov Poll conducted in October 2020 found that charging time and the hassle of charging was one of the reasons drivers weren’t comfortable with the idea of switching to an electric vehicle. As such, developing a widespread and reliable network of public charging stations will go a long way in encouraging individuals to exchange their petrol and diesel-powered vehicles for zero-emission EVs. President Joe Biden is of the same school of thought, and his ambitious American Jobs Plan would see the government invest $174 billion on boosting EV supply chains, subsidizing the cost of EVs for consumers, and developing a massive network of 500,000 public charging stations.

At the moment, there are an estimated 42,490 public EV charging stations in the country, compared to 115,000 gas stations, most of which have several pumps. If Biden’s plan is successful, the government would deploy hundreds of thousands of charging stations by 2030, just five years short of 2035 when several American automakers have pledged to go fully electric. But studies show that most EV drivers charge at home, and the government will have to find ways to ensure middle- and lower-income families that cannot afford to install home chargers aren’t left out.

Scott Hardman, a researcher who has been studying EVs and hybrids at the University of California Davis’ Institute of Transportation Studies, says that ultimately home charging is the most important if the government wishes to increase EV adoption. The Biden administration has plans to propose credits supporting the installation of home chargers, especially for the middle- and lower-income families that make up most of the population.

The quest for a reliable charging network for EVs is being helped by the work of for-profit entities such as Ideanomics Inc. (NASDAQ: IDEX), which are helping to establish wireless charging facilities for electric vehicles.

NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

A group of researchers from Pacific Northwest, Lawrence Berkeley and Sandia national laboratories have discovered a mineral that can absorb uranium from ground water. The researchers discovered the mineral, which is known as calcium apatite, at a former uranium mill in Colorado. The sponge-like mineral reduced the levels of uranium in groundwater significantly.

The project’s lead Mark Rigali, a geochemist from Sandia, stated that apatite technology was also found to decrease the concentration of molybdenum, vanadium and uranium in the groundwater at Colorado’s Rifle mine site. Additionally, it ensures that the uranium amounts remain below the target concentration set by the Department of Energy.

The contaminated mill site is found roughly 180 miles west of Denver. Since the early 2000s, the Office of Legacy Management in the Department of Energy has utilized the site in testing various uranium-remediation technologies.

While vanadium and molybdenum are toxic in high concentrations and beneficial at low levels, uranium in all its forms is known to be toxic when ingested and is also radioactive. Calcium apatite is commonly utilized in fertilizers and is also a prominent component of teeth and bones. The researchers made the ground material into a sponge by introducing sodium phosphate and calcium citrate, which are nontoxic chemicals, into a well that has been created to inject solutions underground.

After the solution has been introduced into the ground, bacteria in the soil consumed the calcium citrate and excreted calcium, which then reacted with sodium phosphate, leading to the formation of calcium apatite. This is what coats soil and sand particles underground to form the apatite sponge. This sponge, which can hold contaminants for millennia, is what captures uranium.

Lawrence Berkeley’s environmental remediation and water resources program lead Ken Williams notes that uranium remediation using the apatite-based approach is the most effective approach that doesn’t have any considerable negative side effects.

Remediation refers to the measures carried out to decrease radiation exposure from existing contamination. This remediation technology was designed by Robert Moore, a former chemical engineer in Sandia. It has been utilized at the Hanford Site in Washington State to prevent strontium-90 from seeping into the Columbia River. Strontium is a radioactive isotope.

Rigali reveals that apatite technology may also be used in other locations that are also contaminated. He explains that the apatite family of minerals is huge, noting that each mineral has different capabilities for storing and capturing contaminants. Rigali adds that an apatite’s structure can be altered to absorb specific contaminants.

For instance, copper apatite is suited in capturing arsenic.

With companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) expressing interest in helping the U.S. federal government to clean up legacy mine sites, the more options for soaking up the contamination, the better.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

• Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition
• CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions
• One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis
• CNS recently announced it will be included in the Russell 2000 Index of small-cap companies for the coming year, effective June 25, which it expects to boost its visibility among investors

As novel biopharmaceutical CNS Pharmaceuticals (NASDAQ: CNSP) approaches its annual meeting of stockholders scheduled for June 28, the company is enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of the company’s lead drug candidate.

The Phase 2 trial will compare the drug Berubicin’s response to established chemotherapy drug lomustine in treating glioblastoma (“GBM”), a fatal class of brain cancers generally considered incurable which usually only leaves patients about 15 months to live on average once they are diagnosed. Patient enrollment began last month across 35 clinical sites in the United States and CNS expects to expand the trial into western Europe during the coming year (https://ibn.fm/KEVIq).

Once about 30 to 50 percent of the patients have reached the six-month point in the trial, CNS will conduct an interim non-binding futility analysis to obtain a snapshot of safety and secondary efficacy outcomes while enrollment otherwise continues.

Berubicin, an anthracycline chemotherapy agent believed to be the first to successfully cross the blood-brain barrier to improve treatment capability, was the subject of a Phase 1 trial 15 years ago that resulted in the long-term survivability of one patient who achieved cancer-free status and continued in that condition during the most recent evaluation conducted in November. Among the other small pool of patients participating at that time, 44 percent saw their disease stabilize or improve, generating optimism for the drug’s potential (https://ibn.fm/gQBzo).

CNS’s efforts have generated interest in the investment community that resulted in the company’s selection to be added to the Russell 2000 Index effective June 25, when the index undergoes its annual reconstitution, according to a news release announcement June 17 (https://ibn.fm/Pj9pQ).

The reconstitution draws in the largest U.S. stocks each year and provides a benchmark measure consulted by investment managers and institutional investors for active investment strategies. The Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market, a subset of the Russell 3000 Index that represents about 10 percent of the total market capitalization of that index, according to the announcement.

“We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index. As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (GBM), we believe this inclusion well-positions us to drive market awareness,” CNS Pharmaceuticals CEO John Climaco stated. “We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.”

CNS has sublicensed Berubicin to Polish company WPD Pharmaceuticals, which will commence a similar Phase 2 clinical trial in Europe during 2H 2021. WPD also plans to conduct a clinical trial examining Berubicin’s safety for pediatric malignant glioma patients later in the year, which would be the first significant investigation of the therapy in these brain cancers in children (https://ibn.fm/VEY0J).

WPD is also helping to advance GBM research by participating in an international consortium of industry experts researching the potential of nanoparticles in maximizing the efficiency of radiotherapy in X-ray dosing to end the recurrence of these high-grade tumors while preserving the adjacent healthy tissue (https://ibn.fm/p7Ydz).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Knightscope Inc. has seen a 46% drop in reported crime at one location and has operated over 1,000,000 hours of service for its autonomous security robots nationwide
• The versatility of the robots have seen their deployment in various areas such as airports, manufacturing plants, hospitals, stadiums, residential and commercial properties
• Recently, the Grand Sierra Resort and Casino adopted Knightscope’s K5 robot, aptly named “Jackbot,” to complement the facility’s existing security team
• This marks Knightscope’s growing client base that only confirms what the robots can do while working towards the company’s mission of a safer country

Knightscope’s mission, since its inception back in 2013, has been to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country. Driven by technology and innovation, the company has rolled out three products and overseen a 46% decrease in reported crime in one particular location and has operated well in excess of 1 million hours across the country. The company currently holds contracts across 6 U.S. time zones (https://ibn.fm/zKXC5).

So far, Knightscope’s products operate in various areas of application including, but not limited to airports, manufacturing plants, hospitals, stadiums, residential and commercial properties, and numerous corporate campuses. In a client catalogue that seems to be steadily growing given the value proposition that Knightscope offers, the latest name therein has been the Grand Sierra Resort and Casino in Reno, Nevada (https://ibn.fm/qvloP).

The resort features close to 2,000 hotel rooms and suites and a 100,000 square feet casino floor, the largest in northern Nevada (https://ibn.fm/yW2Ll). Additionally, it offers a broad range of dining, nightlife and entertainment options. Its move to adopt a Knightscope ASR to cover the massive facility is a testament to what Knightscope products can do, how dependable they are, and how much value they bring to the table.

Knightscope is known for developing Autonomous Security Robot (“ASR”) products that feature self-driving technology, artificial intelligence (“AI”) and robotics. Its primary offerings are the K1 stationary machine, the K3 indoor machines and the K5 outdoor machine. All these products are developed from the ground up at Knightscope’s Mountain View, California facility.

The Grand Sierra Resort and Casino went with the Knightscope K5 ASR that features two-way communication, 360-degree view cameras, an emergency call button and thermal imaging. Named “Jackbot,” this ASR is meant to work in tandem with the facility’s physical security team and add a layer of security to patrols within the space. It will serve as an extra set of eyes and ears and a much-needed added level of protection for the facility.

There have been concerns regarding the safety of security jobs from automation, and with good reason. With innovations and offerings such as Knightscope’s K1, K3 and K5, it is easy for one to see how, ultimately, they could take over all security jobs. That is, however, not the case.

In an interview with Knightscope’s CEO, William Santana Li, he noted that “The robots are intended to be eyes and ears for the humans, not a one to one replacement (https://ibn.fm/Elwaj).” This is further affirmed by the Grand Sierra Resort and Casino’s adoption and use of the robots for its security needs. The facility’s K5 “Jackbot” is meant to allow officers to see and hear what is going on, communicate with staff and customers through the robot and, when needed, dispatch additional officers. Jackbot is not a replacement but rather a tool that complements the facility’s security personnel, just as Knightscope intended it to be.

As Knightscope’s ASRs continue to log more hours in the field, more data is being collected, facilitating the further improvement of the robots and the value they offer. In addition, establishments such as the Grand Sierra Resort and Casino see the value of the robots, consequently integrating them into their spaces. As such, it is only a matter of time before they become more mainstream, get to serve in more diverse areas and contribute to Knightscope Inc.’s mission of making the United States of America the safest nation in the world.

For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

• “Private Label” division will be the sixth distribution channel for HempFusion and its family of products
• The 10 SKU deal totals approximately $250,000 and is expected to double in revenue size in 2021 and quadruple in 2022
• Company will be expanding its Topeka, Kansas facility to accommodate orders of this magnitude, requiring additional equipment and human capital
• Research and development teams are currently working with an additional 30 products under development for the HempFusion and family of brands

HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) recently announced that a leading national and publicly traded grocery retailer has awarded the health and wellness company a 10 SKU private label deal. The deal marks the official launch of the “Private Label” division, which will be the company’s sixth distribution channel, and the initial order totals approximately $250,000. It is scheduled to ship in July 2021 (https://cnw.fm/ihdVN).

The retailer, whose name was not disclosed due to existing non-disclosure obligations, represents a significant opportunity for the newly launched Private Label division. The 10 SKU deal was primarily due to the performance of HempFusion and its family of products within the retailer’s current distribution network.

“We anticipate that this initial $250,000 order is just the beginning and pending sell-through velocity and distribution, we expect this account to generate north of $500,000 for HempFusion in 2021 and upwards of $1,000,000 or more in 2022,” Jon Visser, HempFusion’s Chief Revenue Officer, said.

Additionally, Co-Founder and CEO Jason Mitchell, N.D., added that the company is honored to receive this award and looks forward to “how this has the potential to significantly contribute to the overall success of this particular retailer and HempFusion and its family of brands.”

To fulfill current and future orders of this magnitude, HempFusion is investing in additional structural support at its distribution facility in Topeka, Kansas. The expansion will include investments in additional equipment and human capital to ensure that the distribution is efficient.

The current family of brands distributed by HempFusion Wellness includes HempFusion, Probulin Probiotics, Biome Research, and HF Labs. These products are distributed to approximately 4,000 retail locations in the United States and select international locations.

The company’s current product portfolio consists of 48 SKUs that include tinctures, proprietary FDA Drug Listed Over-The-Counter (“OTC”) Topicals, Doctor and Practitioner lines, and much more. There are also an additional 30 products that are under development, which is the primary focus of the company’s research and development efforts. Probulin Probiotics is HempFusion’s wholly owned subsidiary, one of the fastest-growing probiotics brands in the United States.

The HempFusion focus for CBD is from the soil to the oil. Not all CBD is created equal, which is why HempFusion uses farming practices and extraction processes that result in a far superior whole food hemp extract. Grown in Europe to EU’s highest standards, HempFusion uses only five select, DNA-verified heirloom hemp strains. The company’s oil extraction uses a proprietary solvent-free CO2 method that yields CBD in a richer, purer oil that contains a higher content of the wide variety of other beneficial cannabinoids and plant compounds. Finally, HempFusion tests all products using an ISO-certified, independent laboratory to identify the cannabinoid and terpene profile, and confirm its organic farming practices have left each product free of      herbicides, pesticides, and heavy metals. All of these reports are available to the public, and the batch report of each product sold is available to the consumer via a QR code on the package.

Leveraging this unique approach and product offering, the company is uniquely positioned to seize current and future growth opportunities on both the cannabidiol and probiotics markets. The global cannabidiol market size was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% during the forecast period of 2021 to 2028, resulting in a market size of approximately $13.4 billion in 2028 (https://cnw.fm/mb9lx). The size of the global probiotics market is also set to expand, from $48.38 billion in 2018 to about $77.09 billion by 2025, expanding at a CAGR of 6.9% during the forecast period (https://cnw.fm/TxHDj).

For more information, visit the company’s website at www.HempFusion.com/corporate-information.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://cnw.fm/CBDHF

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

A recent poll conducted by the Drug Policy Alliance (“DPA”) and the American Civil Liberties Union (“ACLU”) has found that more than half of the voters in America are in favor of the drug war coming to an end and also support the decriminalization of the simple possession of substances which are presently illegal.

The poll was conducted last month and interviewed 800 registered voters. Its results were released just before the 50th anniversary of the declaration of the drug war by former president Richard Nixon, which began a system of mass criminalization, which disproportionately targeted individuals of color. Of those surveyed, more than 60% were found to support the elimination of criminal penalties for drug possession and reinvesting resources used for drug enforcement into addiction and treatment services. Another 65% agreed that the United States should withdraw from the drug war.

Surprisingly, the survey also found that a considerably large number of voters felt that the war on drugs had failed. By party affiliation, 82% of members of the GOP, 85% of independents and 83% of Democrats regarded the war on drugs as a failure.

In a press release, the ACLU Justice Division’s director Udi Ofer stated that President Joe Biden should move to dismantle the system of mass incarceration and overpolicing as per his campaign promises, on the anniversary of the war on drugs. In addition to this, the poll also found that more than 60% of those surveyed believed that the use of drugs shouldn’t be treated as a criminal justice issue and should instead be viewed as a public health issue, while another 61% supported the commuting of sentences for drug-related convictions. An additional 64% supported the revocation of mandatory minimum sentences in cases related to drugs.

Ofer asserted that the time had come to embrace new approaches that treated substance use as a public health issue. He noted that the Biden administration could make progress in ending this racist and harmful war by reducing the sentences of individuals imprisoned for drugs. This, he said, would help decrease the over policing of Brown and Black communities in the United States, as well as decrease the problem of mass incarceration.

President Biden has vocalized his support for ending imprisonment for low-level drug cases, stating that no individual should be incarcerated for using drugs. He added that the country should change the way they dealt with drug abuse. However, the Biden administration has yet to take any steps to alter federal policy. Additionally, the president hasn’t granted presidential clemency to individuals imprisoned for drugs.

Should federal marijuana policy ever be relaxed, industry players such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) will have fewer regulatory headaches to contend with as a degree of uniformity may be brought to the currently fractured industry.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

NetworkNewsWire Editorial Coverage: How and what students learn is always changing, but the landscape has become particularly frantic lately with ubiquitous digital technologies. Digital technologies have changed nearly everything, including the student-school-teacher paradigm from kindergarten to higher education to how and who companies hire. The COVID-19 pandemic, a growing choir of voices calling for educational equality, outlandish tuition costs and even so-called “wokeness” have people and companies rethinking educational dynamics. In the thick of it is the burgeoning educational technology (edtech) industry, which is growing rapidly to meet evolving demand from today’s generation of digitally native learners, as evidenced by both analyst forecast and upstarts such as Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) (Profile) immediately finding customers for its new digital learning platform. The evolution also spotlights other companies in the space, including Chegg Inc. (NYSE: CHGG), Grand Canyon Education Inc. (NASDAQ: LOPE), Stride Inc. (NYSE: LRN) and Strategic Education Inc. (NASDAQ: STRA) for what they bring to the table to help people of all ages learn and excel.

• Growing at a 19.9% CAGR through 2028, the global edtech market is forecast to reach $380 billion.
• Nextech AR Solutions has parlayed its retail technology into its exclusive EdTechX platform.
• EdTechX has been labeled co-sell ready by Microsoft, a designation that should expedite sales.
• Ryerson, Nextech were awarded up to $150,000 for the creation, delivery of AR learning experiences.

Edtech: A $380 Billion Industry

The value of compounding interest comes in handy when considering that analysts at Grand View Research estimate that the global education technology market grew from $86 in 2020 billion to $106 billion in 2021. Grand View forecasts a stunning 19.9% compound annual growth through 2028, implying the market size will surge to $379.8 billion in that time. Fueling the growth is the fact that the movement is global, including emerging markets in Africa where tech is providing wider access to learning.

Looking ahead, the future of education involves considering technology here and on the horizon, including things such as virtual reality (“VR”), augmented reality (“AR”) and machine learning (“ML”). AR has already become incredibly useful and popular today, overlaying real word visuals with computer-generated objects in real time. The utility is amazing, as learning becomes interactive and engaging without the user having to be immersed in a computer-generated world. Grand View sees the global AR market growing also exploding; it forecasts a 43.8% compound annual growth rate to $340.2 billion by 2028.

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) specializes in developing and operating AR platforms, three-dimensional product visualizations, human holograms and 360° portals. The company was voted a 2019 Top-20 Most Promising AR/VR Tech Solutions by CIO Review, and NTAR calls many Fortune 500 companies clients for an array of applications, such as e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

All told, the company has curated more than 4,100 events for clients that hosted in excess of 10 million visitors. That proven technology undergirded the company’s R&D of a new product to disrupt the higher education market. That’s exactly what seems to be happening with the recent launch of EdTechX, a comprehensive education product combining enterprise-scale video streaming, integrated assessments, AR holograms and data analytics.

Augmented and Remote Learning Just Tip of Iceberg

With its flagship business model, Nextech has already made inroads in the higher education markets. Ryerson University, Carnegie Mellon University, University of South Florida, Université Laval (in Quebec City, Quebec) and UN Educational, Scientific and Cultural Organization (“UNESCO”) are just a few of the clients already in the company’s portfolio. Of course, they would be natural fits for EdTechX as well, and some have already made the leap, including Ryerson, Carnegie Mellon and Black Student Fund.

The opportunities are only limited to the imagination. Nextech can provide virtual learning labs, digital courses and poster sessions, live demos and collaborations, Q&A sessions, teaching tools, downloadable course content and more. Applications aren’t limited to the classroom either, with homecoming events, convocations and career fairs all available for design.

As demonstrated in this video, Ryerson and Nextech collaborated to incorporate AR and hologram technologies to develop customized virtual labs for different Ryerson science programs. On June 10, Ryerson and Nextech were jointly awarded from eCampusOntario, a provincial-run program, up to $150,000 for the creation and delivery of AR learning experiences for use within post-secondary education institutions.

Don’t Overlook the Microsoft Effect

With the new EdTechX platform being commercialization, Nextech this month launched its LiveX platform on Microsoft Azure. This presents an opportunity for EdTechX to be seen by the more than 5,300 colleges and universities in the United States and give those educational institutions the change to transform traditional learning and events into digital experiences for the more than 19 million students they enroll.

Only days after the launch, EdTechX was deemed by Microsoft to be co-sell ready, an accomplishment with tremendous implications. Co-seller is the upper echelon of Microsoft partners and is reserved only for elite global independent software vendors (“ISVs”), a branding that speaks volumes to the quality of the technology and platform for potential customers. The Microsoft co-seller process includes building demand, sales planning, sharing sales leads, accelerating partner-to-partner empowered selling and delivering marketplace-led commerce.

“Nextech AR Solutions is helping education institutions digitally transform the way educators teach and the way students learn, by enabling remote experiential learning through EdTechX. Studies have shown that these types of immersive technologies improve student engagement and student outcomes,” commented Nancy Teodoro, education partner lead at Microsoft Canada, on the new agreement.

Attracting Clients, CEO Support

It doesn’t take a Rhodes Scholar to recognize the revenue opportunities involving the exploding edtech and AR markets mentioned above. As it happens, though, Nextech is staring at some of the best up-and-coming markets in general when it comes to attracting clients.

Each year, the U.S. Labor Department releases its forecast for expansion and contraction in specific industries. Look at those estimates released in September shows that Nextech AR and digital experience platform services customers represent eight out of the top 10 for fastest-growing industries.

Genuine passion for management is always encouraging for stakeholders to see, but it pales in comparison to a CEO repeatedly laying out money to keep building a position. Nextech CEO Evan Gappelberg wears his optimism about the future of the company on his sleeve for the world to see.

In May, Gappelberg made his seventh purchase of Nextech stock in the last year-and-a-half. This time he exercised warrants for $186,650 worth of stock, putting money in the company’s coffers while increasing his overall holdings to 9.86 million shares. Gappelberg explained his outlook on the company in depth during a recent Nextech presentation at the 2021 LD Micro Invitational.

Getting in Front of the New Way to College

How big is a big enough market opportunity? $100 billion? $500 billion? Fact is that while size is important, it is timing the penetration of the market that generally determines if a company can capture any share. Edtech, AR and other digital learning technologies still have a lot of runway to grow long legs in the coming years. Traditional universities are going to have to learn to adapt, while others are already charting a good course.

Chegg Inc. (NYSE: CHGG), a digital textbook rental service and loose version of an online tutor, is wildly popular among high school and college students the world over. The company’s newest offering, launched this month, is branded Uversity, a platform that facilitates educators and faculty members share things such as notes, videos and practice tests with Chegg members, albeit students or educators.

Grand Canyon Education Inc. (NASDAQ: LOPE) (“GCE”) provides a spate of education services to 26 colleges and universities in the United States, including learning management systems, internal administrations, academic services, counseling services and more. GCE has developed significant technological solutions, infrastructure and operational processes to provide superior services that support the students, faculty and staff of its partner institutions.

Stride Inc. (NYSE: LRN) is a technology-based education company that provides proprietary and third-party online curriculum, software systems, and educational services to facilitate individualized learning for students primarily in kindergarten through 12th grade (K-12) in the United States and internationally. A key opinion leader as well, a recent survey conducted by Stride with third-party research provider Qualtrics determined that most parents want more choices and experience for their kids when it comes to education, especially established virtual learning platforms.

Strategic Education Inc. (NASDAQ: STRA) is an education services holding company best known for its for-profit online schools Capella University and Strayer University, as well as non-degree programs schools such as DevMountain, Hackbright Academy, and Sophia Learning. Capella is expanding its degrees while keeping the workload flexible for its students. More than 10,000 students are now part of the FlexPath program, which allows students to move at their own pace but incentivizes them to go quickly through a pay schedule based on time rather than credit hours.

Where education is going next will likely remain fluid, but the standard of most students attending a four-year, on-campus university looks to be shifting. Technology has changed that forever with the potential to earn the same degree via different channels. Companies that are getting in front of the new paradigm, especially those leaning on technology, should prosper going forward.

For more information about Nextech AR Solutions, please visit Nextech AR Solutions.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

• Battery-powered electric vehicles are set to be a significant demand driver for silver in coming years
• The expected increase in annual silver demand from the electric vehicle sector over the next four years is estimated to equal 10% of 2021’s global silver production
• Excellon Resources is currently executing ongoing precious metals projects in Mexico, Idaho and Germany
• The company recently revealed that its Mexican operations resulted in a 37% YoY increase in silver production as of the fourth quarter of 2020

Fifty grams is slightly more than the weight of an average golf ball, yet it also represents the estimated silver content contained within a battery electric vehicle (“BEV”) (https://ibn.fm/IzGx9). Silver has historically enjoyed widespread usage within the automotive sector, a reflection of its superior electrical conductivity properties, excellent oxide resistance and durability under harsh operating environments. With electric vehicles rapidly rising as a proportion of global automotive sales, the sector is transforming into a powerful demand center for silver, with The Silver Institute forecasting that the automotive industry will absorb nearly 90 million ounces of silver annually by 2025, a significant increase from this year’s anticipated demand of 61 million ounces (1,900t). To put that figure into context, the expected annual demand from the electric vehicle sector is expected to increase over the next four years to over 10 percent of annual global silver production, based on 2021 projections (https://ibn.fm/ZuQCf). The surge in demand should be particularly advantageous for companies such as Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany.

Silver’s unique properties make it difficult to replace across a wide and growing array of automotive applications; furthermore, and unlike platinum group metals, the use of silver is not concentrated within a single automotive component like a catalytic converter. Rather, silver components can be found across a myriad of vehicular applications, including reversing cameras, automotive lenses, and fuel management systems, making the precious metal relatively harder to substitute. A recent study carried out by The Silver Institute has estimated the average internal combustion engine (“ICE”) vehicle to consume 15-28 grams (0.5-0.9 ounces) of silver, a figure which would increase to 18-34 grams for hybrid vehicles and to 25-50 grams for the average BEV. Notably, that figure does not take into account ancillary services which also require the use of silver, such as the construction of charging stations and charging points for electric vehicles.

While silver’s longer-term demand outlook looks bright, driven by surging demand from electric vehicle manufacturers as well as from the solar/photovoltaic industry where silver is a key component utilized in the manufacture of solar cells, sustained growth in silver mine production will necessitate further investment to bring earlier stage projects into production, thereby offsetting losses from reserve depletion and grade decline.

Excellon Resources is currently working towards developing a precious metals growth pipeline across a myriad of geographies, including: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho boasting strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany. Excellon has seen particularly promising results from its Platosa Mine located in Durango, Mexico. Over the course of 2020, the company revealed that its Mexican-based mining operations had resulted in a 37 percent year-over-year increase in silver production, with lead output rising by 32 percent and zine production growing by 19 percent (https://ibn.fm/kQwN4).

Excellon has also updated the market in April 2021 of the results of further underground expansion and exploration drilling at the Platosa Mine, which resulted in the discovery of additional high-grade silver deposits. As per the company’s announcement, further definition and expansion of the Guadalupe North, 623, NE-1 and NE-1S mantos, with results from underground drilling including:

• 1,293 g/t silver equivalent (“AgEq”) over 6.5 metres (618 g/t Ag, 10.1% Pb and 12.0% Zn) in EX21UG565;
• 1,571 g/t AgEq over 4.6 metres (688 g/t Ag, 14.5% Pb and 14.9% Zn) in EX21UG564; and
• 1,031 g/t AgEq over 4.6 metres (359 g/t Ag, 4.9% Pb and 15.9% Zn) in EX20UG522A, including 1,531 g/t AgEq over 1.3 metres (573 g/t Ag, 8.6% Pb and 21.5% Zn).

With rising environmental awareness and a growing transition away from fossil fuels set to drive further growth of both the electric vehicle and photovoltaic sectors, silver demand and price momentum are expected to continue their ongoing rise in the coming future. Through its various projects and ongoing production momentum, Excellon Resources looks well positioned to capitalize on the precious metal’s renaissance.

For more information, visit the company’s website at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

• The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress
• EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine
• Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO

In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it is co-sponsoring a study focused on treating frontline clinicians experiencing COVID-related distress (https://ibn.fm/NvMAo). In addition to co-sponsoring the study, Cybin also announced the development of EMBARK, a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine.

“Our nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest among us,” said Dr. Alex Belser, Cybin’s chief clinical officer. “They’re experiencing high levels of anxiety, depression and burnout. Now it’s our turn to help them. We are sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress.”

The study, which Cybin will be co-sponsoring in a strategic collaboration with the University of Washington, will be hosted in Seattle, one of the cities hit hardest at the outset of the pandemic, and will be led by Dr. Anthony Back, a recognized leader in the fields of palliative care and oncology. The randomized, placebo-controlled trial of psychedelic-assisted psychotherapy with psilocybin will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals.

“There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future,” said Back, who will serve as primary investigator to the clinical trial.

Designed to support the initiative, Cybin’s EMBARK model was developed by Belser and PhD candidate Bill Brennan. Cybin noted that the development of EMBARK has been guided by leading process evidence for the clinical efficacy of psychedelic-assisted psychotherapy and demonstrated theories of therapeutic action to support healing. “EMBARK was designed as a transdiagnostic psychotherapy model that can be adapted to address a range of clinical indications and populations,” the company stated.

“For more than a year now, frontline clinicians and healthcare professionals have made immeasurable sacrifices to protect public health in their communities,” said Cybin CEO Doug Drysdale. “We consider it an honor and our duty to now help support their own healing processes, post-COVID-19. We are also delighted and proud to launch EMBARK, a ground-breaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics. We look forward to working with and supporting Dr. Anthony Back on this important program.”

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
• Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
• BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way

Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (https://ibn.fm/eX4AD).

Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (https://ibn.fm/6C81O). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when coupled with talking therapy (https://ibn.fm/BW9pa). This breakthrough could potentially have profound implications for a space that has seen few pharmacological advancements over recent decades regarding the treatment of mental disorders affecting millions of people around the world, including depression, anxiety, PTSD, addiction, and more. Still, experts caution that more research is needed.

This is where the partnership between Brain Scientific and Ehave can potentially make a difference. The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI and linked data protocols to develop neural net algorithms. As an initial use case, the neural net algorithm would be used to upload an already trained neuronet into a specialized chip, a temporary E-Tattoo, developed by Brain Scientific.

Brain Scientific would also contribute to the collaboration by providing its proprietary data signal acquisition technology, NeuroCap, and NeuroEEG. These devices, designed to collect and read brain activity, would be linked to the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the required software, and hardware and will develop and validate products within three months of receiving any specifications from Ehave.

As part of the MoU, Ehave’s role would be to acquire real-time patients data from Brain Scientific’s NeuroCap and NeuroEEG and transfer it into a cloud. Both Ehave and Brain Scientific will jointly own the data from this collaboration.

In addition, Ehave could seek to leverage its network of partner healthcare providers, including psychiatrists, psychologists, psychotherapists, and general practitioners, to use NeuroCap and NeuroEEG in clinical settings and collect the data about the electrophysiological changes in brain pre, mid and post-psychedelic drug administration.

The collaboration could lead to building or partnering with functional labs where NeuroCap and NeuroEEG devices could be deployed to conduct market studies on consumer behavior and psychology and collect data on various brain-related physiological and mental disorders. These labs are likely to start in Australia and could be rolled out in other parts of the world where Ehave has its footprint.

With E-Tattoo, an EEG device about the size of a stamp, Brain Scientific allows continuous measurement of patients’ brain activity in a non-intrusive way and with minimal distraction from everyday life. Brain Scientific believes that the future of EEG testing will be based on non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. Graphene, often called the wonder material of the 21st century, could potentially allow the development of smaller electrodes — even thinner than a human hair. The two companies are poised to leverage their unique expertise and work together to make a big step forward in neurological and psychiatric research by utilizing graph-based AI and linked data protocols to help develop biomarkers for psychiatric disorders.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.